UB Paderborn / Katalog / Suche / in CDI

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023-05, Vol.26 (3), p.393-404

2023

Link zum Volltext

Verfügbarkeit prüfen

Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?

Journal of gastrointestinal surgery, 2017-03, Vol.21 (3), p.425-433

2017

Link zum Volltext

Verfügbarkeit prüfen

Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study

International journal of cancer, 2018-05, Vol.142 (9), p.1890-1900

2018

Link zum Volltext

Verfügbarkeit prüfen

Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population

Asia-Pacific journal of clinical oncology, 2023-02, Vol.19 (1), p.214-225

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors

Targeted oncology, 2022-03, Vol.17 (2), p.141-151

2022

Link zum Volltext

Verfügbarkeit prüfen

Assessing quality of life (QoL) of patients and their caregivers on phase I clinical trials

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e23130-e23130

2019

Link zum Volltext

Verfügbarkeit prüfen

Maximising Capacity and Saving Cost in an Outpatient Chemotherapy Centre during a Pandemic: A Quality Improvement Project

Blood, 2020-11, Vol.136 (Supplement 1), p.25-26

2020

Link zum Volltext

Verfügbarkeit prüfen

PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases

Clinical cancer research, 2021-04, Vol.27 (7), p.1875-1881

2021

Link zum Volltext

Verfügbarkeit prüfen

MO34-4 Advanced hepatocellular carcinoma viral status and immunotherapy efficacy: A propensity-score matched analysis

Annals of oncology, 2023-11, Vol.34, p.S1417-S1418

2023

Link zum Volltext

Verfügbarkeit prüfen

Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directions

Cancer treatment reviews, 2024-04, Vol.125, p.102700-102700, Article 102700

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS4173-TPS4173

2021

Link zum Volltext

Verfügbarkeit prüfen

Value-driven colorectal cancer survivorship through partnership with primary care

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.6649-6649

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 76

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(74)

Publikationsform

Artikel
(76)

Sprache

Englisch
(76)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Reducing Chemotherapy Waiting Times in the Ambulatory Setting of a Tertiary Cancer Centre Using a Design Thinking Approach

MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models

PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein

Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors

Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series

Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein

A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies

Whole Exome Sequencing of Multi-Regional Biopsies from Metastatic Lesions to Evaluate Actionable Truncal Mutations Using a Single-Pass Percutaneous Technique

Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial

Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model

Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer

Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?

Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study

Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population

Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors

Statistical Process Control Charts for Monitoring Next-Generation Sequencing and Bioinformatics Turnaround in Precision Medicine Initiatives

Assessing quality of life (QoL) of patients and their caregivers on phase I clinical trials

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Maximising Capacity and Saving Cost in an Outpatient Chemotherapy Centre during a Pandemic: A Quality Improvement Project

PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases

MO34-4 Advanced hepatocellular carcinoma viral status and immunotherapy efficacy: A propensity-score matched analysis

Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directions

Phase II study of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)

Value-driven colorectal cancer survivorship through partnership with primary care

Suchergebnisse filtern